ArticleEndocrine connections2025
Induction of type 2 and 3 deiodinase in the blood cells of critically ill patients.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Altered type 2 and 3 deiodinase (D2 and D3) can disrupt thyroid hormone metabolism and contribute to non-thyroidal illness syndrome (NTIS). The impact of the colocalization of D2 and D3, and their expression in immune cells isolated from critically ill patients, are still not fully understood. Our objective was to assess the D2 and D3 in the neutrophils and monocytes of patients admitted to the intensive care unit (ICU) for any cause. Blood samples were collected from 96 ICU patients at admission and on day 7. We employed different cell gradients and flow cytometry to separate and purify cells from whole blood. Parameters indicating redox balance were measured, including total carbonyls, sulfhydryl content and glutathione (GSH) levels. The expression and colocalization of DIO2 and DIO3 were evaluated through RNAscope, real-time PCR (polymerase chain reaction) and immunofluorescence. The formation of carbonyls, a marker for oxidative damage to proteins, was elevated in all patients, while sulfhydryl and GSH levels were found to be reduced. The expression of DIO2 and DIO3 in neutrophils and monocytes from both surviving and deceased patients demonstrated significant variations in localization. Notably, elevated levels of D3 protein showed distinct distribution patterns between the groups. Levels of T3 in each cell type varied and were correlated with patient outcomes. The specific distribution of these enzymes has also been associated with prognosis. The set of these findings enhances our understanding of the pathophysiology of NTIS and may provide valuable information for prognostic assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.